MBX Biosciences Reports Positive One-Year Phase 2 Data for Canvuparatide in Chronic Hypoparathyroidism
MBX has more than doubled off its 52-week low of $9.43 on elevated volume (4.5× avg).
Summary
MBX Biosciences reported positive one-year Phase 2 data for its chronic hypoparathyroidism drug, canvuparatide, demonstrating sustained efficacy and safety, and confirming its path to a Phase 3 trial in Q3 2026.
Key Events · Product Development and Regulatory · MBX
-
Positive One-Year Phase 2 Data
Canvuparatide achieved a 57% responder rate at one year, maintaining serum calcium, reducing urine calcium, and improving kidney function, consistent with restoration of systemic PTH activity.
-
Once-Weekly Dosing Supported
Pharmacokinetic data from the Phase 2 trial continued to support the potential for convenient once-weekly administration with consistent drug concentration and a low peak-to-trough ratio.
-
Favorable Safety Profile
The drug was generally well tolerated through one year of treatment, with no new safety signals observed and most adverse events being mild or moderate in severity.
-
Phase 3 Trial On Track
The company reiterated its plan to initiate the pivotal Phase 3 trial for canvuparatide in Q3 2026, following these positive results.
Analysis · MBX · Life Sciences
MBX Biosciences announced strong one-year data from its Phase 2 trial and open-label extension for canvuparatide, a potential once-weekly PTH replacement therapy. The data showed sustained efficacy with a 57% responder rate, a consistent pharmacokinetic profile supporting once-weekly dosing, and a favorable safety profile. This positive clinical update confirms the drug's potential and keeps the Phase 3 pivotal trial on track for Q3 2026, significantly de-risking the development pathway for a key pipeline asset.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 35.8% of the 1190 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.45%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MBX was trading at $35.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $9.43 to $45.85. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.